VRTX

503.25

0.47% -2.39

시간 외 거래: 505.50 2.25 +0.45%

버텍스 파마슈티컬 (VRTX)

개요 뉴스 가격 이력 옵션 체인 Financials VRTX 왜 하락? 토론 예측 주식 분할

전일 마감가:

$505.64

열려 있는:

$503.14

하루 거래량:

1.49M

Relative Volume:

1.21

시가총액:

$127.55B

수익:

$12.34B

순이익/손실:

$4.34B

주가수익비율:

29.83

EPS:

16.8685

순현금흐름:

$3.71B

1주 성능:

-0.69%

1개월 성능:

-4.85%

6개월 성능:

+13.37%

1년 성능:

+19.49%

1일 변동 폭

$498.90

$507.87

1주일 범위

$496.15

$511.50

52주 변동 폭

$402.58

$560.25

버텍스 파마슈티컬 Stock (VRTX) Company Profile

명칭

Vertex Pharmaceuticals Inc

부문

Healthcare (1058)

산업

Biotechnology (594)

전화

(617) 341-6393

주소

50 NORTHERN AVENUE, BOSTON, MA

직원

6,400

트위터

@VertexPharma

다음 수익 날짜

2026-11-02

최신 SEC 제출 서류

VRTX's Discussions on Twitter

Compare VRTX vs MRNA, REGN, ARGX, RVMD

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VRTX Vertex Pharmaceuticals Inc	503.25	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	197.00	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	739.57	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	818.63	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.12	43.93B	742.00K	-1.37B	-1.07B	-7.0731

버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-18	업그레이드	Maxim Group	Hold → Buy
2026-03-10	개시	Jefferies	Buy
2026-03-10	재확인	Oppenheimer	Outperform
2026-02-13	업그레이드	Oppenheimer	Perform → Outperform
2026-01-28	재개	Barclays	Overweight
2026-01-22	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2026-01-12	업그레이드	Bernstein	Mkt Perform → Outperform
2026-01-07	재개	UBS	Buy
2026-01-06	업그레이드	Wolfe Research	Peer Perform → Outperform
2025-12-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-11-13	개시	Scotiabank	Sector Outperform
2025-09-25	업그레이드	Leerink Partners	Market Perform → Outperform
2025-09-03	개시	Raymond James	Mkt Perform
2025-08-06	업그레이드	Wells Fargo	Equal Weight → Overweight
2025-05-07	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-05-06	다운그레이드	Leerink Partners	Outperform → Market Perform
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-02-12	업그레이드	Canaccord Genuity	Sell → Hold
2025-02-11	업그레이드	Canaccord Genuity	Sell → Hold
2025-01-30	다운그레이드	Wells Fargo	Overweight → Equal Weight
2024-12-20	재확인	H.C. Wainwright	Buy
2024-12-19	다운그레이드	Oppenheimer	Outperform → Perform
2024-12-09	업그레이드	Jefferies	Hold → Buy
2024-11-14	개시	Citigroup	Buy
2024-10-16	개시	Scotiabank	Sector Perform
2024-10-10	재개	Raymond James	Mkt Perform
2024-08-05	다운그레이드	Barclays	Overweight → Equal Weight
2024-06-27	개시	Redburn Atlantic	Buy
2024-04-11	업그레이드	Evercore ISI	In-line → Outperform
2024-02-15	개시	Wolfe Research	Outperform
2024-02-06	다운그레이드	Evercore ISI	Outperform → In-line
2024-02-02	다운그레이드	Bernstein	Outperform → Mkt Perform
2024-01-31	다운그레이드	Maxim Group	Buy → Hold
2024-01-31	다운그레이드	Robert W. Baird	Neutral → Underperform
2024-01-24	다운그레이드	Canaccord Genuity	Hold → Sell
2023-12-14	재확인	RBC Capital Mkts	Sector Perform
2023-05-30	개시	William Blair	Outperform
2023-05-04	재개	Piper Sandler	Overweight
2023-03-21	개시	Bernstein	Outperform
2023-01-18	개시	Canaccord Genuity	Hold
2023-01-17	업그레이드	SVB Leerink	Mkt Perform → Outperform
2022-12-19	다운그레이드	Jefferies	Buy → Hold
2022-07-13	개시	Cantor Fitzgerald	Overweight
2022-06-01	업그레이드	Maxim Group	Hold → Buy
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-05-06	다운그레이드	Robert W. Baird	Outperform → Neutral
2022-05-03	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2022-02-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-01-27	재확인	JP Morgan	Overweight
2022-01-27	재확인	Morgan Stanley	Underweight
2022-01-27	재확인	RBC Capital Mkts	Outperform
2022-01-27	재확인	Stifel	Hold
2022-01-27	재확인	Wolfe Research	Outperform
2022-01-20	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-12-09	개시	Wells Fargo	Overweight
2021-11-19	개시	BMO Capital Markets	Market Perform
2021-11-19	다운그레이드	Piper Sandler	Overweight → Neutral
2021-09-09	다운그레이드	Stifel	Buy → Hold
2021-09-07	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2021-07-20	다운그레이드	SVB Leerink	Mkt Perform → Underperform
2021-07-19	재개	Wolfe Research	Outperform
2021-07-01	개시	Raymond James	Mkt Perform
2021-06-11	다운그레이드	Daiwa Securities	Outperform → Neutral
2021-02-23	업그레이드	Robert W. Baird	Neutral → Outperform
2021-02-02	재확인	H.C. Wainwright	Buy
2020-12-30	개시	Daiwa Securities	Outperform
2020-11-30	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2020-11-20	개시	Bernstein	Outperform
2020-10-28	개시	UBS	Buy
2020-07-31	재확인	H.C. Wainwright	Buy
2020-07-08	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-04-30	재확인	H.C. Wainwright	Buy
2020-04-28	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2020-03-04	개시	Barclays	Overweight
2020-01-31	다운그레이드	Robert W. Baird	Outperform → Neutral
2019-11-19	업그레이드	Guggenheim	Neutral → Buy
2019-11-12	개시	SunTrust	Buy
2019-10-17	재개	BofA/Merrill	Buy
2019-09-03	업그레이드	Goldman	Neutral → Buy
2019-08-01	다운그레이드	Needham	Buy → Hold
2019-05-23	재개	Citigroup	Buy
2019-05-21	개시	Credit Suisse	Outperform
2019-04-12	개시	Evercore ISI	In-line
2019-03-26	업그레이드	William Blair	Mkt Perform → Outperform
2019-03-19	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2019-02-06	다운그레이드	Maxim Group	Buy → Hold

모두보기

버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스

Oct 01, 2026

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey

Oct 01, 2026

M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - PharmaLive

Oct 01, 2026

Sep 29, 2026

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 29, 2026

Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha

Sep 29, 2026

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool

Sep 29, 2026

Sep 28, 2026

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance

Sep 28, 2026

Vertex Pharmaceuticals stock last trades at USD 526.66 on September 28, 2026 - AD HOC NEWS

Sep 28, 2026

Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance

Sep 28, 2026

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo

Sep 28, 2026

Sep 27, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 27, 2026

Sep 26, 2026

Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - Fortune

Sep 26, 2026

Sep 25, 2026

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. - Barron's

Sep 25, 2026

Sep 24, 2026

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Sep 24, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 24, 2026

Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail

Sep 24, 2026

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail

Sep 24, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026

Sep 23, 2026

Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance

Sep 23, 2026

Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com

Sep 23, 2026

Allstate, Autozone, Vertex Pharmaceuticals - TradingView

Sep 23, 2026

Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research

Sep 23, 2026

Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research

Sep 23, 2026

Vertex reports positive Phase IIb data as it completes enrollment in pivotal AMKD trial - The Pharma Letter

Sep 23, 2026

Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire

Sep 23, 2026

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance

Sep 23, 2026

Jefferies raises Vertex stock price target on kidney drug data By Investing.com - Investing.com Canada

Sep 23, 2026

Vertex reports results from Phase IIb AMPLIFIED trial for AMKD - Clinical Trials Arena

Sep 23, 2026

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating - Yahoo Finance

Sep 23, 2026

What could reshape the outlook for Vertex Pharmaceuticals (NASDAQ:VRTX) now? - Kalkine Media

Sep 23, 2026

Sep 22, 2026

Vertex Pharma stock gains 3 percent ahead of the open - AD HOC NEWS

Sep 22, 2026

The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily

Sep 22, 2026

Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com

Sep 22, 2026

Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga

Sep 22, 2026

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance

Sep 22, 2026

Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's

Sep 22, 2026

BMO reiterates Vertex stock rating on positive trial data By Investing.com - Investing.com Canada

Sep 22, 2026

Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS

Sep 22, 2026

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial - BioSpace

Sep 22, 2026

Vertex’s midstage data amplify kidney disease market opportunity - Fierce Biotech

Sep 22, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Sep 22, 2026

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria - TradingView

Sep 22, 2026

Urine protein fell 42.7% in a kidney trial. Vertex finished enrolling its next study. - Stock Titan

Sep 22, 2026

Inside the Vertex Pharmaceuticals (VRTX) Story Reshaping Healthcare Stocks Sentiment - Kalkine Media

Sep 22, 2026

Sep 21, 2026

Vertex Pharma stock slips 1.55 percent pre-market before the open - ad-hoc-news.de

Sep 21, 2026

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 11.97% Potential Upside - DirectorsTalk Interviews

Sep 21, 2026

Fierce Biotech Layoff Tracker 2026: Novo reveals 4k more employees were laid off; Sionna halves staff - Fierce Biotech

Sep 21, 2026

Sep 18, 2026

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Sep 18, 2026